Prelude Therapeutics (PRLD) News Today $1.30 +0.41 (+46.40%) (As of 12/20/2024 05:40 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Prelude Therapeutics Incorporated (NASDAQ:PRLD) CFO Bryant David Lim Buys 25,000 SharesDecember 21 at 8:06 AM | insidertrades.comFueling growth: The Innovation Space powers breakthroughs in life sciences, clean technologies, and advanced materialsDecember 20 at 2:32 PM | bizjournals.comPrelude Therapeutics Incorporated (NASDAQ:PRLD) CFO Acquires $22,750.00 in StockPrelude Therapeutics Incorporated (NASDAQ:PRLD - Get Free Report) CFO Bryant David Lim purchased 25,000 shares of Prelude Therapeutics stock in a transaction dated Thursday, December 19th. The stock was bought at an average price of $0.91 per share, with a total value of $22,750.00. Following the acquisition, the chief financial officer now directly owns 27,400 shares of the company's stock, valued at approximately $24,934. This trade represents a 1,041.67 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.December 20 at 1:36 PM | marketbeat.comKrishna Vaddi Buys 100,000 Shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD) StockPrelude Therapeutics Incorporated (NASDAQ:PRLD - Get Free Report) CEO Krishna Vaddi purchased 100,000 shares of the business's stock in a transaction that occurred on Wednesday, December 18th. The stock was acquired at an average price of $0.93 per share, for a total transaction of $93,000.00. Following the purchase, the chief executive officer now owns 1,167,275 shares of the company's stock, valued at approximately $1,085,565.75. This represents a 9.37 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.December 20 at 1:36 PM | marketbeat.comPrelude Therapeutics (NASDAQ:PRLD) Given "Market Outperform" Rating at JMP SecuritiesDecember 13, 2024 | americanbankingnews.comPrelude Therapeutics Shares Promising Data for CDK9 Inhibitor PRT2527December 13, 2024 | msn.comPrelude Therapeutics (PRLD) Gets a Sell from Morgan StanleyDecember 12, 2024 | markets.businessinsider.comPrelude Therapeutics presents first interim data from trial of PRT2527December 12, 2024 | markets.businessinsider.comPrelude Therapeutics: Promising Clinical Advancements and Strong Financial Position Drive Buy RatingDecember 11, 2024 | markets.businessinsider.comPrelude Therapeutics price target lowered to $4 from $7 at JMP SecuritiesDecember 11, 2024 | markets.businessinsider.comPrelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid MalignanciesDecember 11, 2024 | globenewswire.comPrelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology SummitNovember 27, 2024 | globenewswire.comPrelude Therapeutics Incorporated (NASDAQ:PRLD) Short Interest UpdatePrelude Therapeutics Incorporated (NASDAQ:PRLD - Get Free Report) was the recipient of a significant growth in short interest in the month of October. As of October 31st, there was short interest totalling 2,940,000 shares, a growth of 18.1% from the October 15th total of 2,490,000 shares. Currently, 13.9% of the shares of the company are sold short. Based on an average trading volume of 340,700 shares, the short-interest ratio is presently 8.6 days.November 17, 2024 | marketbeat.comPrelude Therapeutics (PRLD) Receives a Sell from BarclaysNovember 9, 2024 | markets.businessinsider.comPrelude Therapeutics Reports Q3 2024 Results and Clinical ProgressNovember 9, 2024 | msn.comPrelude Therapeutics' (PRLD) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright restated a "buy" rating and set a $5.00 target price on shares of Prelude Therapeutics in a research report on Friday.November 8, 2024 | marketbeat.comPrelude Therapeutics: Promising Developments and Strategic Collaborations Drive Buy RatingNovember 7, 2024 | markets.businessinsider.comPrelude Therapeutics Shows Strong Q3 2024 Financial ResultsNovember 7, 2024 | markets.businessinsider.comPrelude Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 6, 2024 | finance.yahoo.comOptimism in Prelude Therapeutics: Buy Rating Backed by Promising PRT3789 Trial ResultsOctober 28, 2024 | markets.businessinsider.comPrelude Therapeutics (NASDAQ:PRLD) Receives "Buy" Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $5.00 target price on shares of Prelude Therapeutics in a research note on Monday.October 28, 2024 | marketbeat.comPrelude Therapeutics price target lowered to $1 from $3 at BarclaysOctober 27, 2024 | markets.businessinsider.comPrelude Therapeutics: Sell Rating Due to Limited Efficacy Improvement and Financial ChallengesOctober 26, 2024 | markets.businessinsider.comPrelude Therapeutics Shares Promising Phase 1 Trial Data for PRT3789 at International SymposiumOctober 26, 2024 | msn.comCautious Outlook on Prelude Therapeutics: Sell Rating Amid Modest Trial Results and Market SkepticismOctober 26, 2024 | markets.businessinsider.comPrelude Therapeutics presents new data from Phase 1 trial of PRT3789October 25, 2024 | markets.businessinsider.comBuy Rating Affirmed for Prelude Therapeutics Amid Positive Developments in PRT3789 and Strong Financial PositionOctober 25, 2024 | markets.businessinsider.comPrelude Therapeutics Presents New Data from SMARCA Degrader Portfolio at the 36th EORTC-NCI-AACR SymposiumOctober 24, 2024 | globenewswire.comPrelude Therapeutics Incorporated (NASDAQ:PRLD) Sees Significant Decline in Short InterestPrelude Therapeutics Incorporated (NASDAQ:PRLD - Get Free Report) saw a significant decrease in short interest during the month of September. As of September 30th, there was short interest totalling 2,490,000 shares, a decrease of 25.2% from the September 15th total of 3,330,000 shares. Based on an average daily volume of 282,900 shares, the short-interest ratio is currently 8.8 days. Approximately 11.7% of the company's stock are sold short.October 13, 2024 | marketbeat.comPrelude Therapeutics Showcases Innovative SMARCA Degrader Programs at Barcelona SymposiumOctober 10, 2024 | msn.comPrelude Therapeutics Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR SymposiumOctober 9, 2024 | globenewswire.comPrelude Therapeutics (NASDAQ:PRLD) Stock Quotes, Forecast and News SummaryOctober 1, 2024 | benzinga.comShort Interest in Prelude Therapeutics Incorporated (NASDAQ:PRLD) Increases By 37.0%Prelude Therapeutics Incorporated (NASDAQ:PRLD - Get Free Report) saw a significant growth in short interest in September. As of September 15th, there was short interest totalling 3,330,000 shares, a growth of 37.0% from the August 31st total of 2,430,000 shares. Currently, 15.7% of the shares of the stock are sold short. Based on an average daily trading volume, of 261,900 shares, the short-interest ratio is currently 12.7 days.September 29, 2024 | marketbeat.comHC Wainwright & Co. Upgrades Prelude Therapeutics (PRLD)September 20, 2024 | msn.comHC Wainwright Upgrades Prelude Therapeutics (NASDAQ:PRLD) to "Strong-Buy"HC Wainwright raised shares of Prelude Therapeutics from a "hold" rating to a "strong-buy" rating in a report on Thursday.September 20, 2024 | marketbeat.comPrelude Therapeutics (PRLD) Gets a Sell from BarclaysSeptember 16, 2024 | markets.businessinsider.comJMP Securities Reaffirms "Market Outperform" Rating for Prelude Therapeutics (NASDAQ:PRLD)JMP Securities reissued a "market outperform" rating and set a $7.00 price target on shares of Prelude Therapeutics in a research note on Monday.September 16, 2024 | marketbeat.comBuy Rating Affirmed for Prelude Therapeutics on Promising PRT3789 Trial Results and Strong Financial PositionSeptember 16, 2024 | markets.businessinsider.comPrelude Therapeutics Releases Promising Phase 1 Data on Novel Cancer TreatmentSeptember 16, 2024 | msn.comPrelude Therapeutics: Uncertainties in Drug Efficacy and Dosing Prompt Sell RatingSeptember 14, 2024 | markets.businessinsider.comPrelude Therapeutics’ SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 TrialSeptember 13, 2024 | markets.businessinsider.comPrelude Announces Phase 1 Data Of PRT3789 Trial For Cancer Treatment; Stock FallsSeptember 13, 2024 | markets.businessinsider.comPrelude Therapeutics' SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 TrialSeptember 13, 2024 | globenewswire.comHold Rating on Prelude Therapeutics Pending PRT3789 Trial ResultsSeptember 11, 2024 | markets.businessinsider.comHC Wainwright Reaffirms "Neutral" Rating for Prelude Therapeutics (NASDAQ:PRLD)HC Wainwright reiterated a "neutral" rating and issued a $5.00 target price on shares of Prelude Therapeutics in a research note on Tuesday.September 10, 2024 | marketbeat.comPrelude Therapeutics (NASDAQ:PRLD) Shares Up 2.3%Prelude Therapeutics (NASDAQ:PRLD) Trading 2.3% HigherSeptember 10, 2024 | marketbeat.comPrelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024September 9, 2024 | globenewswire.comPRLD Sep 2024 2.500 put (PRLD240920P00002500)August 25, 2024 | finance.yahoo.comQ3 2024 Earnings Estimate for Prelude Therapeutics Incorporated Issued By HC Wainwright (NASDAQ:PRLD)Prelude Therapeutics Incorporated (NASDAQ:PRLD - Free Report) - Equities research analysts at HC Wainwright decreased their Q3 2024 earnings per share (EPS) estimates for Prelude Therapeutics in a note issued to investors on Thursday, August 15th. HC Wainwright analyst R. Burns now anticipates thAugust 19, 2024 | marketbeat.comPRLD Sep 2024 10.000 call (PRLD240920C00010000)August 18, 2024 | finance.yahoo.com Get Prelude Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRLD and its competitors with MarketBeat's FREE daily newsletter. Email Address URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight. >> Register for the Workshop Now PRLD Media Mentions By Week PRLD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PRLD News Sentiment▼1.690.61▲Average Medical News Sentiment PRLD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PRLD Articles This Week▼61▲PRLD Articles Average Week Get Prelude Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRLD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Lyell Immunopharma News Opthea News Genfit News Alector News Gossamer Bio News Amarin News Kyverna Therapeutics News MediWound News TuHURA Biosciences News Sagimet Biosciences News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PRLD) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prelude Therapeutics Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Prelude Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PRLD Stock Alerts